ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

Open Vet J. 2025; 15(1): 151-161


Neuroprotection effect of bovine umbilical mesenchymal stem cell-conditioned medium on the rat model of Alzheimer’s disease mediated by upregulation of BDNF and NGF and downregulation of TNF-α and IL-1β

Hevi Wihadmadyatami, Muhammad Ali Zulfikar, Herawati Herawati, Srikanth Karnati, Golda Rani Saragih, Dinda Aliffia, Dyah A.O.A. Pratama, Nurrahmi Handayani, Ulayatul Kustiati, Dewi Ratih Tirtosari, Yudy Tjahjono.




Abstract
Cited by 0 Articles

Background:
Neurodegenerative diseases (NDD) are distinguished by impairment and depletion of nerve cells; one of the most common NDDs is Alzheimer's Disease (AD), which can appear in early onset or late onset. In recent years, the secretome or conditioned medium of mesenchymal stem cells provides new hope for improving conditions and preventing AD. One of the secretomes is bovine umbilical mesenchymal stem cells conditioned medium (BUMSC-CM), where BUMSC is predicted to promote neuronal proliferation potentially.

Aim:
This study analyzes the therapeutic efficiency of conditioned medium or secretome produced from BUMSC-CM in treating neurodegeneration in animal models of AD.

Methods:
Five groups consisting of twenty-five male rats were assigned: untreated (Group A, n=5), positive control group given normal saline 1 ml/100 g BW (Group B, n=5), AD rats model followed by Donepezil treatment (Group C, n=5), AD rats model with BUMSC-CM 0.2 ml/kg BW post-TMT induction (Group D, n=5), and AD rats model with BUMSC-CM 0.5 ml/kg BW post-TMT induction (Group E, n=5). Brain samples were analyzed for neuronal density using cresyl violet staining. The expression and activity of BDNF were analyzed by ELISA, in addition IL-1β, TNF-α, and NGF were analyzed by qPCR. Interactions between the main substances of BUMSC-CM and beta-amyloid protein were visualized using in silico molecular docking.

Results:
Our result demonstrated that BUMSC-CM with the dosage of 0,5 ml/kg BW significantly increased BDNF concentration. We also found that BUMSC-CM with dosage 0.2 ml/kg BW and 0.5 ml/kg BW down-regulated IL-1β and TNF-α and upregulated NGF expression. Additionally, the number of neurons in AD rats post-treated with BUMSC-CM was significantly increasing. Furthermore, the amino acids in BUMSC-CM, including isoleucine, leucine, and valine, bind to amyloid beta protein via interactions that are hydrophobic and hydrogen-bonded.

Conclusion:
In this study, the neuroprotective potential of BUMSC-CM was demonstrated by its ability to upregulate BDNF and NGF while downregulating IL-1β and TNF-α. Additionally, BUMSC-CM showed potential to promote neuron proliferation in the hippocampus regions of a rat AD model. The main constituents in BUMSC-CM adhere to amyloid beta protein, hence diminishing the likelihood of neurodegenerative disorders, specifically AD.

Key words: Alzheimer’s disease, BUMSC-CM, Rat Model, TNF-α, IL-1β





publications
0
supporting
0
mentioning
0
contrasting
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.



Bibliomed Article Statistics

30
30
33
R
E
A
D
S

16

9

20
D
O
W
N
L
O
A
D
S
020304
2025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.


We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More Info Got It!